Serveur d'exploration sur Heinrich Schütz

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Stoffwechsel und Analyse von Leukotrienen in vivo

Identifieur interne : 001384 ( Main/Exploration ); précédent : 001383; suivant : 001385

Stoffwechsel und Analyse von Leukotrienen in vivo

Auteurs : D. Keppler

Source :

RBID : ISTEX:4010E799B631240493F7ABC3C70791AF6458B8FB

Abstract

Summary: Leukotrienes are potent mediators of inflammatory and allergic reactions involved, among others, in endotoxin action and shock, tissue trauma, acute liver injury, hepatorenal syndrome, inflammatory bowel disease, acute pancreatitis, and asthma. Studies on metabolism and analysis of these arachidonate metabolites in vivo are a prerequisite for an improved understanding of their role under physiological and pathophysiological conditions and for the development of inhibitors of leukotriene synthesis and of receptor antagonists. Leukotriene C4 and its metabolites, collectively termed the cysteinyl leukotrienes, are predominantly inactivated by the liver. Rapid hepatocellular uptake is followed by partial metabolic inactivation, comprising ω-oxidation and N-acetylation of leukotriene E4, and excretion into bile. A minor portion of the cysteinyl leukotrienes undergoes enterohepatic circulation. In all species investigated so far, hepatobiliary elimination of cysteinyl leukotrienes predominates over renal excretion. Analysis of the systemic production of cysteinyl leukotrienes in vivo has been accomplished by radioimmunological determination of species-characteristic index metabolites in bile after their separation by high-performance liquid chromatography. The mercapturate N-acetyl-leukotriene E4 is the index metabolite of choice in the rat. In man, leukotriene E4 is the predominant endogenous cysteinyl leukotriene in both bile and urine. The amounts of cysteinyl leukotrienes detected under various pathophysiological conditions may be sufficient to induce known phenomena associated with the respective disease. As shown under experimental conditions, inhibition of leukotriene synthesis or receptor antagonism can serve as therapeutic approaches.


Url:
DOI: 10.1007/BF01733441


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="de">Stoffwechsel und Analyse von Leukotrienen in vivo</title>
<author>
<name sortKey="Keppler, D" sort="Keppler, D" uniqKey="Keppler D" first="D." last="Keppler">D. Keppler</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4010E799B631240493F7ABC3C70791AF6458B8FB</idno>
<date when="1988" year="1988">1988</date>
<idno type="doi">10.1007/BF01733441</idno>
<idno type="url">https://api.istex.fr/document/4010E799B631240493F7ABC3C70791AF6458B8FB/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000F87</idno>
<idno type="wicri:Area/Main/Curation">000F78</idno>
<idno type="wicri:Area/Main/Exploration">001384</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="de">Stoffwechsel und Analyse von Leukotrienen in vivo</title>
<author>
<name sortKey="Keppler, D" sort="Keppler, D" uniqKey="Keppler D" first="D." last="Keppler">D. Keppler</name>
<affiliation>
<wicri:noCountry code="subField">Heidelberg</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Klinische Wochenschrift</title>
<title level="j" type="abbrev">Klin Wochenschr</title>
<idno type="ISSN">0023-2173</idno>
<idno type="eISSN">1432-1440</idno>
<imprint>
<publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="1988-10-01">1988-10-01</date>
<biblScope unit="volume">66</biblScope>
<biblScope unit="issue">20</biblScope>
<biblScope unit="page" from="997">997</biblScope>
<biblScope unit="page" to="1004">1004</biblScope>
</imprint>
<idno type="ISSN">0023-2173</idno>
</series>
<idno type="istex">4010E799B631240493F7ABC3C70791AF6458B8FB</idno>
<idno type="DOI">10.1007/BF01733441</idno>
<idno type="ArticleID">Art1</idno>
<idno type="ArticleID">BF01733441</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0023-2173</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="de">de</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Summary: Leukotrienes are potent mediators of inflammatory and allergic reactions involved, among others, in endotoxin action and shock, tissue trauma, acute liver injury, hepatorenal syndrome, inflammatory bowel disease, acute pancreatitis, and asthma. Studies on metabolism and analysis of these arachidonate metabolites in vivo are a prerequisite for an improved understanding of their role under physiological and pathophysiological conditions and for the development of inhibitors of leukotriene synthesis and of receptor antagonists. Leukotriene C4 and its metabolites, collectively termed the cysteinyl leukotrienes, are predominantly inactivated by the liver. Rapid hepatocellular uptake is followed by partial metabolic inactivation, comprising ω-oxidation and N-acetylation of leukotriene E4, and excretion into bile. A minor portion of the cysteinyl leukotrienes undergoes enterohepatic circulation. In all species investigated so far, hepatobiliary elimination of cysteinyl leukotrienes predominates over renal excretion. Analysis of the systemic production of cysteinyl leukotrienes in vivo has been accomplished by radioimmunological determination of species-characteristic index metabolites in bile after their separation by high-performance liquid chromatography. The mercapturate N-acetyl-leukotriene E4 is the index metabolite of choice in the rat. In man, leukotriene E4 is the predominant endogenous cysteinyl leukotriene in both bile and urine. The amounts of cysteinyl leukotrienes detected under various pathophysiological conditions may be sufficient to induce known phenomena associated with the respective disease. As shown under experimental conditions, inhibition of leukotriene synthesis or receptor antagonism can serve as therapeutic approaches.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Keppler, D" sort="Keppler, D" uniqKey="Keppler D" first="D." last="Keppler">D. Keppler</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/corpus/SchutzV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001384 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    SchutzV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4010E799B631240493F7ABC3C70791AF6458B8FB
   |texte=   Stoffwechsel und Analyse von Leukotrienen in vivo
}}

Wicri

This area was generated with Dilib version V0.6.20.
Data generation: Sun Apr 10 01:23:10 2016. Site generation: Fri Aug 18 21:45:27 2017